Key Takeaways
- FDA received 990 adverse event reports for compounded semaglutide and over 730 for compounded tirzepatide as of May 31, 2026.
- Compounded GLP‑1s haven’t undergone FDA safety, effectiveness or quality review and may contain wrong ingredients or dosing.
- FDA urges clinicians and patients to rely on FDA‑approved products and report any adverse events via MedWatch.
What risks do compounded GLP‑1s pose?
Compounded GLP‑1s skip FDA review for safety, effectiveness and quality before reaching patients. The FDA logged 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide as of May 31, 2026—a total exceeding 1,700 that likely undercounts the true number, since many state‑licensed pharmacies aren’t required to report such events (fda.gov). Some reports involved hospitalizations for nausea, vomiting, abdominal pain and other serious symptoms stemming from dosing errors and inconsistent dosing practices (fda.gov).
Why are these compounded versions riskier than approved drugs?
The FDA doesn’t review compounded GLP‑1 medications before they’re sold, leaving questions about quality, correct dosage and sterility unanswered. FDA investigators found dosing errors when patients or clinicians miscalculated amounts—sometimes administering 5 to 20 times the intended dose—because varying concentrations, vial formats and unit differences made the math error-prone (fda.gov). Compounded versions may use salt forms like semaglutide acetate or sodium, which differ from the approved base form; the FDA can’t confirm they work the same way (fda.gov).
What is FDA advising clinicians and patients to do?
The FDA says clinicians should consider compounded GLP‑1s only when a patient’s needs can’t be met by an FDA‑approved product and should exercise extra care with dosing and administration (fda.gov). Patients should fill prescriptions at state‑licensed pharmacies and watch for misleading telehealth marketing—claims that compounded products are “the same” as FDA‑approved drugs or FDA‑approved themselves (fda.gov). Report any adverse events to FDA MedWatch (fda.gov).
FAQ
What are compounded GLP‑1s?
Compounded GLP‑1s are semaglutide or tirzepatide formulations mixed by pharmacies rather than manufactured under FDA‑approved processes. They haven’t been reviewed for safety or quality by the FDA.
How many adverse events have there been with compounded GLP‑1s?
As of May 31, 2026, FDA recorded 990 reports for compounded semaglutide and more than 730 for compounded tirzepatide—over 1,700 total, likely underreported.
Why haven’t compounded GLP‑1s gone through FDA review?
Compounded drugs are made per prescription for individual patients. They bypass the FDA review process required for manufactured products, so safety, dosage and purity can vary.
What types of adverse events have been reported?
Reported problems include serious digestive symptoms, dehydration, pancreatitis, dosing errors leading to 5–20 times the intended dose, hospitalizations and potentially dangerous misdosing.
Can clinicians prescribe compounded GLP‑1s safely?
Clinicians may consider compounded GLP‑1s only when FDA‑approved options aren’t suitable. They must calculate dosing carefully and instruct patients clearly—these products carry extra risks.
Not medical advice. GLP-1 medications are prescription drugs that require clinical supervision. Talk to a licensed healthcare provider before starting, stopping, or changing any treatment.
Adverse-event reports are safety signals, not proof that a compounded drug caused each reported event. FDA notes that other factors may contribute.